Rx-to-OTC Switch

Browse Rx-to-OTC Switch Content

Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville today released the below statement following the U.S. Food and Drug Administration (FDA) approving Opill®

Jul 13, 2023

CHPA today released the below statement following a U.S. Food and Drug Administration (FDA) joint advisory committee meeting, which concluded that Opill®, a once-daily oral contraceptive, should be approved as the first oral contraceptive for use without a prescription:  

May 10, 2023

The Consumer Healthcare Products Association (CHPA) today released the below statement following the U.S. Food and Drug Administration’s (FDA) public release of briefing materials

May 5, 2023

CHPA applauds FDA for taking a critical step forward today in public health, which will remove many of the barriers and stigmas attached to this life-saving emergency therapy for opioid overdoses

Mar 29, 2023

The Consumer Healthcare Products Association (CHPA) released the following statement in advance of FDA Advisory Committee meetings considering OTC access to naloxone

Feb 15, 2023

Don't miss CHPA President & CEO, Scott Melville's insights on the consumer healthcare industry for the year ahead. Check out this article from Chain Drug Review.

Jan 9, 2023

CHPA Submits Comments on FDA Proposed Rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use

Nov 22, 2022

CHPA appreciates the opportunity to provide input for Agency consideration as it works to finalize the regulations for ACNU.

Nov 21, 2022

Filter Results